Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension
Abstract Introduction Here we report the intraocular pressure (IOP) changes following treatment with latanoprostene bunod (LBN) 0.024% in patients in Canadian ophthalmology practices. Methods This real-world, open-label, 6-week, observational study collected data from 59 Canadian ophthalmologists an...
Sábháilte in:
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Adis, Springer Healthcare
2025-04-01
|
| Sraith: | Ophthalmology and Therapy |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1007/s40123-025-01132-z |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|